- Home
- RCUS vs AUTL Comparison
RCUS vs AUTL Comparison
Compare RCUS & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCUS
- AUTL
- Stock Information
- Founded
- RCUS 2015
- AUTL 2014
- Country
- RCUS United States
- AUTL United Kingdom
- Employees
- RCUS N/A
- AUTL N/A
- Industry
- RCUS Biotechnology: Pharmaceutical Preparations
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RCUS Health Care
- AUTL Health Care
- Exchange
- RCUS Nasdaq
- AUTL Nasdaq
- Market Cap
- RCUS 1.4B
- AUTL 609.4M
- IPO Year
- RCUS 2018
- AUTL 2018
- Fundamental
- Price
- RCUS $13.81
- AUTL $2.21
- Analyst Decision
- RCUS Buy
- AUTL Strong Buy
- Analyst Count
- RCUS 12
- AUTL 3
- Target Price
- RCUS $34.50
- AUTL $10.20
- AVG Volume (30 Days)
- RCUS 626.1K
- AUTL 1.7M
- Earning Date
- RCUS 02-19-2025
- AUTL 11-12-2024
- Dividend Yield
- RCUS N/A
- AUTL N/A
- EPS Growth
- RCUS N/A
- AUTL N/A
- EPS
- RCUS N/A
- AUTL N/A
- Revenue
- RCUS $263,000,000.00
- AUTL $10,091,000.00
- Revenue This Year
- RCUS $127.65
- AUTL $851.83
- Revenue Next Year
- RCUS N/A
- AUTL $264.18
- P/E Ratio
- RCUS N/A
- AUTL N/A
- Revenue Growth
- RCUS 119.17
- AUTL 82.71
- 52 Week Low
- RCUS $13.51
- AUTL $2.07
- 52 Week High
- RCUS $20.31
- AUTL $7.37
- Technical
- Relative Strength Index (RSI)
- RCUS 33.05
- AUTL 35.87
- Support Level
- RCUS $13.51
- AUTL $2.17
- Resistance Level
- RCUS $15.62
- AUTL $2.80
- Average True Range (ATR)
- RCUS 0.60
- AUTL 0.17
- MACD
- RCUS -0.16
- AUTL 0.02
- Stochastic Oscillator
- RCUS 11.67
- AUTL 19.18
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.